Canada · Delayed Price · Currency is CAD RAMM Pharma Statistics
Total Valuation
RAMM Pharma has a market cap or net worth of CAD 596,947. The enterprise value is 619,366.
| Market Cap | 596,947 |
| Enterprise Value | 619,366 |
Important Dates
The next estimated earnings date is Monday, March 1, 2027.
| Earnings Date | Mar 1, 2027 |
| Ex-Dividend Date | n/a |
Share Statistics
RAMM Pharma has 119.39 million shares outstanding.
| Current Share Class | 119.39M |
| Shares Outstanding | 119.39M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 31.43% |
| Owned by Institutions (%) | n/a |
| Float | 81.87M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.47 |
| PB Ratio | 0.16 |
| P/TBV Ratio | 0.16 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.49 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.28, with a Debt / Equity ratio of 0.05.
| Current Ratio | 0.28 |
| Quick Ratio | 0.16 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.13 |
| Interest Coverage | -17.82 |
Financial Efficiency
Return on equity (ROE) is -112.44% and return on invested capital (ROIC) is -32.51%.
| Return on Equity (ROE) | -112.44% |
| Return on Assets (ROA) | -24.54% |
| Return on Invested Capital (ROIC) | -32.51% |
| Return on Capital Employed (ROCE) | -113.53% |
| Weighted Average Cost of Capital (WACC) | 29.59% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.12 |
| Inventory Turnover | 0.54 |
Taxes
In the past 12 months, RAMM Pharma has paid 10,699 in taxes.
| Income Tax | 10,699 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -66.67% in the last 52 weeks. The beta is 0.39, so RAMM Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.39 |
| 52-Week Price Change | -66.67% |
| 50-Day Moving Average | 0.02 |
| 200-Day Moving Average | 0.03 |
| Relative Strength Index (RSI) | 40.27 |
| Average Volume (20 Days) | 71,143 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, RAMM Pharma had revenue of CAD 1.27 million and -9.08 million in losses. Loss per share was -0.08.
| Revenue | 1.27M |
| Gross Profit | 750,369 |
| Operating Income | -4.25M |
| Pretax Income | -9.07M |
| Net Income | -9.08M |
| EBITDA | -3.96M |
| EBIT | -4.25M |
| Loss Per Share | -0.08 |
Balance Sheet
The company has 147,129 in cash and 169,552 in debt, with a net cash position of -22,423 or -0.00 per share.
| Cash & Cash Equivalents | 147,129 |
| Total Debt | 169,552 |
| Net Cash | -22,423 |
| Net Cash Per Share | -0.00 |
| Equity (Book Value) | 3.75M |
| Book Value Per Share | 0.03 |
| Working Capital | -2.14M |
Cash Flow
| Operating Cash Flow | -1.26M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 287,648 |
| Net Borrowing | -69,793 |
| Free Cash Flow | -1.26M |
| FCF Per Share | -0.01 |
Margins
| Gross Margin | 59.14% |
| Operating Margin | -335.10% |
| Pretax Margin | -714.73% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
RAMM Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -1,521.06% |
| FCF Yield | -211.35% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
RAMM Pharma has an Altman Z-Score of -17.57 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -17.57 |
| Piotroski F-Score | 2 |